Clinical Trials Browser

INDUSTRY × fludarabine × 30 days × Clear all

NCT03967223 2026-04-17

IGNYTE-ESO

Phase 2 Active not recruiting

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT05826535 2026-04-17

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Phase 1/2 Recruiting

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT04923893 2026-04-13

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT06577025 2026-04-13

aMMbition

Phase 2 Active not recruiting

Multiple Myeloma

NCT07149857 2026-04-13

CARTITUDE-10

Phase 2 Recruiting

Multiple Myeloma

NCT07523529 2026-04-13

SELECT-2CAR

Phase 1/2 Recruiting

BreastCNSGastrointestinalGenitourinaryGynecologic

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT02625480 2026-04-09

ZUMA-4

Phase 1/2 Completed

Recurrence, Lymphoma, B-Cell

NCT05993299 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Neoplasms

NCT06703346 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

Neoplasms

NCT06193889 2026-04-06

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Phase 2/3 Recruiting

Autoimmune Diseases, Myasthenia Gravis

NCT06773091 2026-04-06

NKSOLID

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07510815 2026-04-06

DUAL-MESO-NK

Phase 1/2 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT04673617 2026-04-03

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

Lymphoma, Lymphoma, Non-Hodgkin

NCT07284433 2026-04-02

QUADvance

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Phase 1/2 Active not recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT07500220 2026-03-30

DUET-HCC

Phase 1/2 Recruiting

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Liver Neoplasms

NCT07502287 2026-03-30

DUAL-NK-NB

Phase 1/2 Recruiting

Neuroblastoma, Recurrence, Ganglioneuroblastoma

NCT06413498 2026-03-27

iMMagine-3

Phase 3 Recruiting

Multiple Myeloma

NCT06834282 2026-03-27

CertainT-1

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07492628 2026-03-25

DUET-UC-NK

Phase 1 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07015242 2026-03-24

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Phase 2 Recruiting

Lymphoma

NCT07486089 2026-03-20

DUAL-NK-BC

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms